Immunoscore and Immunoprofiling in cancer: an update from the melanoma and immunotherapy bridge 2015
about
Excerpts from the 1st international NTNU symposium on current and future clinical biomarkers of cancer: innovation and implementation, June 16th and 17th 2016, Trondheim, Norway.SOX2 immunity and tissue resident memory in children and young adults with glioma.T cell receptor repertoire usage in cancer as a surrogate marker for immune responses.Monitoring immune-checkpoint blockade: response evaluation and biomarker development.Oncolytic VSV Primes Differential Responses to Immuno-oncology Therapy.Combination Treatment of Patients with BRAF-Mutant Melanoma: A New Standard of Care.Exosomes carrying immunoinhibitory proteins and their role in cancer.Metabolism shapes the tumor microenvironment.Computer-assisted stereology and automated image analysis for quantification of tumor infiltrating lymphocytes in colon cancer.The Oncopig Cancer Model: An Innovative Large Animal Translational Oncology Platform.Immunomodulatory Monoclonal Antibodies in Combined Immunotherapy Trials for Cutaneous MelanomaApplication of ImmunoScore Model for the Differentiation between Active Tuberculosis and Latent Tuberculosis Infection as Well as Monitoring Anti-tuberculosis Therapy.Tertiary Lymphoid Structures Associate with Tumour Stage in Urothelial Bladder Cancer.Beyond PD-L1 testing-emerging biomarkers for immunotherapy in non-small cell lung cancer.Immunogenomic Classification of Colorectal Cancer and Therapeutic Implications.The Immunoscore system predicts prognosis after liver metastasectomy in colorectal cancer liver metastases.Immunogenetics of prostate cancer: a still unexplored field of study.Adrenergic Signaling: A Targetable Checkpoint Limiting Development of the Antitumor Immune Response.T cells specific for a TAP-independent self-peptide remain naïve in tumor-bearing mice and are fully exploitable for therapy.Immune profiling of melanoma tumors reflecting aggressiveness in a preclinical model.Sexual Dimorphism of Immune Responses: A New Perspective in Cancer Immunotherapy.Quantitative Analysis of Immune Infiltrates in Primary Melanoma.PD-L1 and PD-1 and characterization of tumor-infiltrating lymphocytes in high grade sarcomas of soft tissue - prognostic implications and rationale for immunotherapy.PD-L1 inhibitors in the pipeline: Promise and progress.Explaining the Paucity of Intratumoral T Cells: A Construction Out of Known Entities.Immune cell profiling in cancer: molecular approaches to cell-specific identification.Further Advances in Cancer Immunotherapy: Going Beyond Checkpoint Blockade.Genetically Induced Tumors in the Oncopig Model Invoke an Antitumor Immune Response Dominated by Cytotoxic CD8β+ T Cells and Differentiated γδ T Cells Alongside a Regulatory Response Mediated by FOXP3+ T Cells and Immunoregulatory Molecules.Oncograms Visualize Factors Influencing Long-Term Survival of Cancer Patients Treated with Adenoviral Oncolytic Immunotherapy.Prognostic Implications of Heterogeneity in Intra-tumoral Immune Composition for Recurrence in Early Stage Lung Cancer
P2860
Q37349280-92A37D42-14B8-4286-8894-A1706E9925CDQ38373829-3CFBD9FF-DF22-4EFE-8152-96520660FF41Q38376433-E1FBFF31-F05D-4D39-9FC3-977C6BC6C108Q38666241-69346CB8-EA11-49CF-BBBF-0598F6FA27E9Q38746023-D44CB738-A46F-43A6-A93F-BC167B82C8EDQ39069585-AB4C6255-D289-4F47-9253-F691185D82B4Q39215663-DEB216F8-D116-472F-B42E-88926BC4CCA8Q39367096-DB26B0F6-6CF9-4EDD-9247-5D25F2844C22Q40500354-3F5471AC-E9D4-4277-8FC0-AFA8E858F2C5Q41526718-CB42DB8A-9340-4718-A9CB-E0C92AF8D915Q42362520-F6196509-AE9C-4EC3-9224-4BF96385A0EAQ44230087-58C204F6-5A7A-4980-9281-80630DBCA571Q44959093-244B66AC-AC06-4530-8B85-C65764B573E1Q47101079-54B28979-E0BD-4B62-9344-26BEB0E241E5Q47323319-242FC232-DC73-4C72-964F-1B04BEEED531Q48182409-FFDBAA22-C717-414D-BDAF-7F0D6E81B132Q50082109-590CE442-7F27-4CAD-BC66-2E634A211D14Q50286895-BD8E6CF6-3175-406F-B0EB-95854562EA56Q50420406-42EBE00D-D1A1-43D6-9BDB-7DA4AAA19DFEQ51795679-783E82F3-3196-4B25-8914-B0D7BFF87E85Q52606149-7D3D86B1-1849-4F95-8FF1-78EE87A47FEBQ52691700-7B7CEE9E-65C4-41CE-ABDE-D3D6ECE2ACD0Q52699886-FC880287-419B-4205-A159-76F4B7192790Q52731766-15AABB9A-B4B5-4B02-8395-99B6F0770388Q53369837-57B8BDC5-2A91-43DE-A5B9-7014692FE72BQ54947687-0E395C79-36CF-4C59-BF23-B878322F7FF0Q55122005-C6047C89-31E3-4ED7-A7AD-05A9FA0E530EQ55292386-8125D8F1-1680-4AB9-AB95-588E03C158DDQ55510561-143D68B5-279F-4F35-9E29-A1DCE3E8E66CQ58122079-74C558BB-94D4-4F50-BBB5-8AAED2FA9B5F
P2860
Immunoscore and Immunoprofiling in cancer: an update from the melanoma and immunotherapy bridge 2015
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on 20 September 2016
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Immunoscore and Immunoprofilin ...... and immunotherapy bridge 2015
@en
Immunoscore and Immunoprofilin ...... and immunotherapy bridge 2015.
@nl
type
label
Immunoscore and Immunoprofilin ...... and immunotherapy bridge 2015
@en
Immunoscore and Immunoprofilin ...... and immunotherapy bridge 2015.
@nl
prefLabel
Immunoscore and Immunoprofilin ...... and immunotherapy bridge 2015
@en
Immunoscore and Immunoprofilin ...... and immunotherapy bridge 2015.
@nl
P2093
P2860
P50
P1476
Immunoscore and Immunoprofilin ...... and immunotherapy bridge 2015
@en
P2093
C B Bifulco
F M Marincola
P2860
P2888
P356
10.1186/S12967-016-1029-Z
P577
2016-09-20T00:00:00Z
P6179
1038714697